Ultra-low cholesterol poses no safety issues, analysis suggests

5d9cf6c8-8067-420e-ab59-562fa4b43927articleimage.jpg

29 Aug 2017 --- Aggressively reducing low-density lipoprotein cholesterol (LCL-C) to ultra-low levels poses no health risks, analysis of research has suggested. It was associated with progressively fewer cardiovascular events and no apparent safety concerns in patients with stable atherosclerotic cardiovascular disease over 2.2 years of follow-up, according to a new analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) trial.

The findings, presented at European Society of Cardiology (ESC) Congress on 27 August and published in The Lancet, “suggest that a lower LDL-C target – far below current guidelines – can safely be considered to further reduce the risk of recurrent cardiovascular events in high risk patients,” says investigator Dr. Robert Giugliano from Brigham and Women’s Hospital and Harvard Medical School in Boston, Massachusetts, US.

“These findings are unique in that they represent the first analysis of a large cohort of patients to achieve such very low LDL-C levels, namely being less than one-third of the most common treatment goal of below 1.8 millimoles per liter (mmol/L) for highest risk patients,” he says.

Lowered levels
The FOURIER trial randomized patients with stable atherosclerotic cardiovascular disease and treated with background statin therapy, to either placebo or evolocumab – a proprotein convertase subtilisin-kexin type 9 (PCSK9) monoclonal antibody.

Initial results from the trial showed that evolocumab lowered LDL-C levels to a median of 0.8 mmol/L and significantly reduced the risk of cardiovascular events at a median follow-up of 2.2 years.

The new analysis examined efficacy and safety endpoints according to degree of LDL-C reduction at one month. In addition, a study known as EBBINGHAUS embedded within the larger analysis explored effects on cognition using a validated tablet-based tool.

A total of 25,982 patients with an LDL-C assessment at week 4 who did not experience a primary efficacy or pre-specified safety event prior to the week 4 visit were included in the analysis.

The study showed that the risk of the primary efficacy endpoint – a composite of cardiovascular death, myocardial infarction, stroke, coronary revascularization or hospitalization for unstable angina declined steadily as LDL-C levels decreased, with no significant association between LDL-C level and adverse events.

A similar reduction was observed in the key secondary endpoint, with 2,669 subjects in the lowest LDL-C category (below 0.5 mmol/L) at four weeks experiencing the lowest rate of cardiovascular death, or myocardial infarction compared to the group with highest LDL-C (above 2.6 mmol/L).

Exploratory analyses in a subgroup of 504 patients with an LDL-C lower than 0.25 mmol/L showed an even further reduction in cardiovascular events with no increase in safety events.

Additionally, among 1,154 patients who underwent formal cognitive testing prior to, or on the first day of study treatment as part of the EBBINGHAUS study, there were no adverse effects on memory, executive function, memory, or reaction time associated with lower LDL-C.

“Although longer-term follow-up will be important, the totality of evidence to date from trials of intensive lipid lowering supports reduction of LDL-C in high-risk patients to levels below those currently recommended in cholesterol guidelines,” notes Dr. Giugliano.

To contact our editorial team please email us at editorial@cnsmedia.com

Related Articles

Nutrition & Health News

Glanbia targets modern lifestyle demands with new performance nutrition ingredients 

17 May 2018 --- Glanbia Nutritionals has launched two new performance nutrition ingredients for formulation in functional beverages in Europe, the Middle East and Africa. Ignitor and WheyXR were developed to enhance amino acid release, allowing manufacturers to maximize the health benefits of protein supplementation. Both ingredients target the ever-expanding market for sports nutrition options and were included in its range of prototypes at this year’s Vitafoods Europe 2018, which showcased Glanbia’s portfolio and applications expertise.

Nutrition & Health News

Major players support WHO call for global elimination of trans fats by 2023

15 May 2018 --- The International Food and Beverage Alliance (IFBA), which brings together 12 leading food and beverage companies, has agreed to help contribute to the WHO goal of eliminating industrially produced trans fats from the global food supply by 2023. The move comes just one month before the June 18th total US ban on trans fats in products. It is encased within a six-step guide called Replace and calls for strong public-private cooperation and product reformulation with the public health in mind.

Nutrition & Health News

One gram of fish oil a day to keep osteoarthritis pain at bay, study suggests

10 May 2018 --- One gram of fish oil a day could help reduce the pain of patients with osteoarthritis, a new study in Rheumatology reports. In the largest, most up to date study of its kind, researchers from the University of Surrey examined the link between diet and the effective self-management of osteoarthritis.

Nutrition & Health News

Despite conflicting advice, eggs not linked to cardiovascular risk, study finds 

07 May 2018 --- University of Sydney researchers are aiming to clear up conflicting dietary advice around egg consumption, as a new study finds that eating up to 12 eggs per week for a year does not increase cardiovascular risk factors in people with pre-diabetes and type 2 diabetes. Their study was published in the American Journal of Clinical Nutrition.

Nutrition & Health News

Kamut wheat-based replacement diet could benefit patients with NAFLD, study shows

03 May 2018 --- Kamut Brand khorasan wheat products may help reduce metabolic risk factors and ameliorate the liver profile in patients with non-alcoholic fatty liver disease (NAFLD), according to a study in The Journal of the American College of Nutrition. Secondary prevention improvements, including the reduction in inflammation and cholesterol, were also evident. 

More Articles
URL : http://www.nutritioninsight.com:80/news/ultra-low-cholesterol-poses-no-safety-issues-analysis-suggests.html